Skip to content

Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?

Search Clinical Trials

Trial Objectives

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).

Who Can Participate

You may be able to join this study if you are at least 18 years old, with medically inoperable Stage I/IIA NSCLC and if you have not received prior anticancer therapy for lung cancer.

Age: 18+ Gender: Any

Estimated Time Commitment

Up to 7 years

Time Commitment Details

If you are eligible and choose to be in the study, your participation will last up to 7 years. You will be asked to visit the study site about 26 times.

Payment & Reimbursement

Payment: Not Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jami Henriksen

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Merck Sharp & Dohme Corp.

Principal Investigators

Laurie L. Carr

Laurie L. Carr, MD


Jeffrey Kern

Jeffrey Kern, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required